Signal transduction via cannabinoid receptors

CNS and Neurological Disorders - Drug Targets

Volumn 8, Issue 6, 2009, Pages 422-431

  Dalton, George D ^a   Bass, Caroline E ^a   Van Horn, Cynthia G ^a   Howlett, Allyn C ^a  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

2 Arachidonoylglycerol; Anandamide; Cannabinoid receptor heteromers; Endocannabinoid; Extracellular signal regulated kinase; G proteins; Peroxisome proliferator activated receptor; Receptor tyrosine kinases

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DRONABINOL; ENDOCANNABINOID; EPIDERMAL GROWTH FACTOR; FATTY ACID; GLUCOSE; GUANINE NUCLEOTIDE BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; OPIATE RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHOLIPASE C; PROTEIN TYROSINE KINASE;

ADIPOCYTE; ADIPOSE TISSUE; APPETITE; AUTOPHOSPHORYLATION; BINDING AFFINITY; BRAIN; CALCIUM TRANSPORT; CELL STRAIN HEK293; CENTRAL NERVOUS SYSTEM; CORPUS STRIATUM; DEPOLARIZATION; DRUG TARGETING; ENERGY BALANCE; FATTY ACID SYNTHESIS; FOOD INTAKE; GLUCOSE HOMEOSTASIS; HUMAN; HYPOTHALAMUS; LIMBIC CORTEX; LIVER; LIVER CELL; METABOLIC REGULATION; NEUROMODULATION; NEUROTRANSMITTER RELEASE; NONHUMAN; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STELLATE CELL;

ANIMALS; HUMANS; RECEPTORS, CANNABINOID; SIGNAL TRANSDUCTION;

EID: 75849131456     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152709789824615     Document Type: Review

References (136)

1. Howlett, A.C.; Barth, F.; Bonner, T.I.; Cabral, G.; Casellas, P.; Devane, W.A.; Felder, C.C.; Herkenham, M.; Mackie, K.; Martin, B.R.; Mechoulam, R.; Pertwee, R.G. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev., 2002, 54, 161-202.
2. Pertwee, R.G. Pharmacological actions of cannabinoids. Handb. Exp. Pharmacol., 2005, 168, 1-51.
3. Childers, S.R. Activation of G-proteins in brain by endogenous and exogenous cannabinoids. AAPS. J., 2006, 8, E112-E117.
4. Howlett, A.C.; Padgett, L.W.; Shim, J.Y. Cannabinoid Agonist and Inverse Agonist Regulation of G-Protein Coupling. Chapter 7, In: The Cannabinoid Receptors; Reggio, P.H., Ed.; USA: Humana Press Inc.: 2009, pp. 173-202.
5. Pertwee, R.G. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci., 2005, 76, 1307-1324.
6. Demuth, D.G.; Molleman, A. Cannabinoid signalling. Life Sci., 2006, 78, 549-563.
7. Diaz-Laviada, I.; Ruiz-Llorente, L. Signal transduction activated by cannabinoid receptors. Mini. Rev. Med. Chem., 2005, 5, 619-630.
8. Howlett, A.C. Cannabinoid receptor signaling. Handb. Exp. Pharmacol., 2005, 168, 53-79.
9. McAllister, S.D.; Glass, M. CB(1) and CB(2) receptor-mediated signalling: a focus on endocannabinoids. Prostaglandins Leukot. Essent. Fatty Acids, 2002, 66, 161-171.
10. Chevaleyre, V.; Takahashi, K.A.; Castillo, P.E. Endocannabinoid-mediated synaptic plasticity in the CNS. Annu. Rev. Neurosci., 2006, 29, 37-76.
11. Freund, T.F.; Katona, I.; Piomelli, D. Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev., 2003, 83, 1017-1066.
12. Kano, M.; Ohno-Shosaku, T.; Hashimotodani, Y.; Uchigashima, M.; Watanabe, M. Endocannabinoid-mediated control of synaptic transmission. Physiol. Rev., 2009, (184), 309-380.
13. Lovinger, D.M. Presynaptic modulation by endocannabinoids. Handb. Exp. Pharmacol., 2008, 84, 435-477.
14. Cabral, G.A.; Raborn, E.S.; Griffin, L.; Dennis, J.; Marciano-Cabral, F. CB2 receptors in the brain: role in central immune function. Br. J. Pharmacol., 2008, 153, 240-251.
15. Centonze, D.; Battistini, L.; Maccarrone, M. The endocannabinoid system in peripheral lymphocytes as a mirror of neuroinflammatory diseases. Curr. Pharm. Des., 2008, 14, 2370-2382.
16. Miller, A.M.; Stella, N. CB2 receptor-mediated migration of immune cells: it can go either way. Br. J. Pharmacol., 2008, 153, 299-308.
17. Wright, K.L.; Duncan, M.; Sharkey, K.A. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br. J. Pharmacol., 2008, 153, 263-270.
18. Hohmann, A.G.; Suplita, R.L. Endocannabinoid mechanisms of pain modulation. AAPS J., 2006, 8, E693-E708.
19. Fernandez-Ruiz, J.; Pazos, M.R.; Garcia-Arencibia, M.; Sagredo, O.; Ramos, J.A. Role of CB2 receptors in neuroprotective effects of cannabinoids. Mol. Cell Endocrinol., 2008, 286, S91-S96.
20. Anand, P.; Whiteside, G.; Fowler, C.J.; Hohmann, A.G. Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res. Rev., 2008, 60(1), 255-266.
21. Marriott, K.S.; Huffman, J.W. Recent advances in the development of selective ligands for the cannabinoid CB(2) receptor. Curr. Top. Med. Chem., 2008, 8, 187-204.
22. Mackie, K. Cannabinoid receptors: where they are and what they do. J. Neuroendocrinol., 2008, 20(Suppl 1), 10-14.
23. Guo, J.; Ikeda, S.R. Endocannabinoids modulate N-type calcium channels and G-protein-coupled inwardly rectifying potassium channels via CB1 cannabinoid receptors heterologously expressed in mammalian neurons. Mol. Pharmacol., 2004, 65, 665-674.
24. Twitchell, W.; Brown, S.; Mackie, K. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J. Neurophysiol., 1997, 78, 43-50.
25. Wilson, R.I.; Kunos, G.; Nicoll, R.A. Presynaptic specificity of endocannabinoid signaling in the hippocampus. Neuron, 2001, 31, 453-462.
26. Deadwyler, S.A.; Hampson, R.E.; Mu, J.; Whyte, A.; Childers, S. Cannabinoids modulate voltage sensitive potassium A-current in hippocampal neurons via a cAMP-dependent process. J. Pharmacol. Exp. Ther., 1995, 273, 734-743.
27. Manzanares, J.; Corchero, J.; Romero, J.; Fernandez-Ruiz, J.J.; Ramos, J.A.; Fuentes, J.A. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol. Sci., 1999, 20, 287-294.
28. Vigano, D.; Rubino, T.; Parolaro, D. Molecular and cellular basis of cannabinoid and opioid interactions. Pharmacol. Biochem. Behav., 2005, 81, 360-368.
29. Devane, W.A.; Spain, J.W.; Coscia, C.J.; Howlett, A.C. An assessment of the role of opioid receptors in the response to cannabimimetic drugs. J. Neurochem., 1986, 46, 1929-1935.
30. Bidaut-Russell, M.; Howlett, A.C. Cannabinoid receptor-regulated cyclic AMP accumulation in the rat striatum. J. Neurochem., 1991, 57, 1769-1773.
31. Childers, S.R.; Fleming, L.; Konkoy, C.; Marckel, D.; Pacheco, M.; Sexton, T.; Ward, S. Opioid and cannabinoid receptor inhibition of adenylyl cyclase in brain. Ann. NY Acad. Sci., 1992, 654, 33-51.
32. Rodriguez, J.J.; Mackie, K.; Pickel, V.M. Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. J. Neurosci., 2001, 21, 823-833.
33. Pickel, V.M.; Chan, J.; Kash, T.L.; Rodriguez, J.J.; Mackie, K. Compartment-specific localization of cannabinoid 1 (CB1) and mu-opioid receptors in rat nucleus accumbens. Neuroscience, 2004, 127, 101-112.
34. Rios, C.; Gomes, I.; Devi, L.A. mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br. J. Pharmacol., 2006, 148, 387-395.
35. Schoffelmeer, A.N.; Hogenboom, F.; Wardeh, G.; De Vries, T.J. Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core. Neuropharmacology, 2006, 51, 773-781.
36. Vaysse, P.J.; Gardner, E.L.; Zukin, R.S. Modulation of rat brain opioid receptors by cannabinoids. J. Pharmacol. Exp. Ther., 1987, 241, 534-539.
37. Kathmann, M.; Flau, K.; Redmer, A.; Trankle, C.; Schlicker, E. Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn Schmiedebergs Arch. Pharmacol., 2006, 372, 354-361.
38. Kracke, G.R.; Stoneking, S.P.; Ball, J.M.; Tilghman, B.M.; Washington, C.C.; Hotaling, K.A.; Johnson, J.O.; Tobias, J.D. The cannabinoid receptor agonists, anandamide and WIN 55,212-2, do not directly affect mu opioid receptors expressed in Xenopus oocytes. Naunyn Schmiedebergs Arch. Pharmacol., 2007, 376, 285-293.
39. Shapira, M.; Gafni, M.; Sarne, Y. Independence of, and interactions between, cannabinoid and opioid signal transduction pathways in N18TG2 cells. Brain Res., 1998, 806, 26-35.
40. Shapira, M.; Vogel, Z.; Sarne, Y. Opioid and cannabinoid receptors share a common pool of GTP-binding proteins in cotransfected cells, but not in cells which endogenously coexpress the receptors. Cell Mol. Neurobiol., 2000, 20, 291-304.
41. Tulunay, F.C.; Ayhan, I.H.; Sparber, S.B. The effects of morphine and delta-9-tetrahydrocannabinol on motor activity in rats. Psychopharmacology (Berl.) 1982, 78, 358-360.
42. Narimatsu, S.; Yamamoto, I.; Watanabe, K.; Yoshimura, H. Change in hypothermia and catalepsy induced by cannabinoids or morphine in mice tolerant to these substances. Eur. J. Pharmacol., 1987, 141, 437-443.
43. Rubino, T.; Forlani, G.; Vigano, D.; Zippel, R.; Parolaro, D. Modulation of extracellular signal-regulated kinases cascade by chronic delta 9-tetrahydrocannabinol treatment. Mol. Cell Neurosci., 2004, 25, 355-362.
44. Rubino, T.; Forlani, G.; Vigano, D.; Zippel, R.; Parolaro, D. Ras/ERK signalling in cannabinoid tolerance: from behaviour to cellular aspects. J. Neurochem., 2005, 93, 984-991.
45. Bass, C.E.; Welch, S.P.; Martin, B.R. Reversal of delta 9-tetrahydrocannabinol-induced tolerance by specific kinase inhibitors. Eur. J. Pharmacol., 2004, 496, 99-108.
46. Valverde, O.; Noble, F.; Beslot, F.; Dauge, V.; Fournie-Zaluski, M.C.; Roques, B.P. Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect. Eur. J. Neurosci., 2001, 13, 1816-1824.
47. Gerald, T.M.; Howlett, A.C.; Ward, G.R.; Ho, C.; Franklin, S.O. Gene expression of opioid and dopamine systems in mouse striatum: effects of CB1 receptors, age and sex. Psychopharmacology (Berl.), 2008, 198(4), 497-508.
48. Navarro, M.; Carrera, M.R.; Fratta, W.; Valverde, O.; Cossu, G.; Fattore, L.; Chowen, J.A.; Gomez, R.; Del, A.I.; Villanua, M.A.; Maldonado, R.; Koob, G.F.; Rodriguez, D.F. Functional interaction between opioid and cannabinoid receptors in drug self-administration. J. Neurosci., 2001, 21, 5344-5350.
49. Walker, J.M.; Hohmann, A.G.; Martin, W.J.; Strangman, N.M.; Huang, S.M.; Tsou, K. The neurobiology of cannabinoid analgesia. Life Sci., 1999, 65, 665-673.
50. Walker, J.M.; Hohmann, A.G. Cannabinoid mechanisms of pain suppression. Handb. Exp. Pharmacol., 2005, 168, 509-554.
51. Houser, S.J.; Eads, M.; Embrey, J.P.; Welch, S.P. Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Delta(9)-THC and anandamide. Brain Res., 2000, 857, 337-342.
52. Welch, S.P.; Eads, M. Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Res., 1999, 848, 183-190.
53. Bloom, A.S.; Dewey, W.L. A comparison of some pharmacological actions of morphine and delta9-tetrahydrocannabinol in the mouse. Psychopharmacology (Berl.), 1978, 57, 243-248.
54. Rubino, T.; Massi, P.; Vigano, D.; Fuzio, D.; Parolaro, D. Long-term treatment with SR141716A, the CB1 receptor antagonist, influences morphine withdrawal syndrome. Life Sci., 2000, 66, 2213-2219.
55. Bernstein, M.A.; Welch, S.P. Effects of spinal versus supraspinal administration of cyclic nucleotide-dependent protein kinase inhibitors on morphine tolerance in mice. Drug Alcohol Depend., 1997, 44, 41-46.
56. Smith, F.L.; Javed, R.; Elzey, M.J.; Welch, S.P.; Selley, D.; Sim-Selley, L.; Dewey, W.L. Prolonged reversal of morphine tolerance with no reversal of dependence by protein kinase C inhibitors. Brain Res., 2002, 958, 28-35.
57. Bernstein, M.A.; Welch, S.P. Inhibition of protein phosphatases alters the expression of morphine tolerance in mice. Eur. J. Pharmacol., 1998, 341, 173-177.
58. Lee, M.C.; Smith, F.L.; Stevens, D.L.; Welch, S.P. The role of several kinases in mice tolerant to delta 9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther., 2003, 305, 593-599.
59. Rubino, T.; Vigano', D.; Massi, P.; Spinello, M.; Zagato, E.; Giagnoni, G.; Parolaro, D. Chronic delta-9-tetrahydrocannabinol treatment increases cAMP levels and cAMP-dependent protein kinase activity in some rat brain regions. Neuropharmacology, 2000, 39, 1331-1336.
60. Vigano, D.; Rubino, T.; Vaccani, A.; Bianchessi, S.; Marmorato, P.; Castiglioni, C.; Parolaro, D. Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems. Psychopharmacology (Berl.), 2005, 182, 527-536.
61. Meschler, J.P.; Howlett, A.C. Signal transduction interactions between CB1 cannabinoid and dopamine receptors in the rat and monkey striatum. Neuropharmacology, 2001, 40, 918-926.
62. Glass, M.; Felder, C.C. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J. Neurosci., 1997, 17, 5327-5333.
63. Kearn, C.S.; Blake-Palmer, K.; Daniel, E.; Mackie, K.; Glass, M. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol. Pharmacol., 2005, 67, 1697-1704.
64. Jarrahian, A.; Watts, V.J.; Barker, E.L. D2 dopamine receptors modulate Galpha-subunit coupling of the CB1 cannabinoid receptor. J. Pharmacol. Exp. Ther., 2004, 308, 880-886.
65. Rhee, M.H.; Nevo, I.; Avidor-Reiss, T.; Levy, R.; Vogel, Z. Differential superactivation of adenylyl cyclase isozymes after chronic activation of the CB(1) cannabinoid receptor. Mol. Pharmacol., 2000, 57, 746-752.
66. Yao, L.; Fan, P.; Jiang, Z.; Mailliard, W.S.; Gordon, A.S.; Diamond, I. Addicting drugs utilize a synergistic molecular mechanism in common requiring adenosine and Gi-beta gamma dimers. Proc. Natl. Acad. Sci. USA, 2003, 100, 14379-14384.
67. Mukhopadhyay, S.; McIntosh, H.H.; Houston, D.B.; Howlett, A.C. The CB(1) cannabinoid receptor juxtamembrane C-terminal peptide confers activation to specific G proteins in brain. Mol. Pharmacol., 2000, 57, 162-170.
68. Wager-Miller, J.; Westenbroek, R.; Mackie, K. Dimerization of G protein-coupled receptors: CB1 cannabinoid receptors as an example. Chem. Phys. Lipids, 2002, 121, 83-89.
69. Mackie, K. Cannabinoid receptor homo- and heterodimerization. Life Sci., 2005, 77, 1667-1673.
70. Marcellino, D.; Carriba, P.; Filip, M.; Borgkvist, A.; Frankowska, M.; Bellido, I.; Tanganelli, S.; Muller, C.E.; Fisone, G.; Lluis, C.; Agnati, L.F.; Franco, R.; Fuxe, K. Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers: a combined neurochemical and behavioral analysis. Neuropharmacology, 2008, 54, 815-823.
71. Carriba, P.; Ortiz, O.; Patkar, K.; Justinova, Z.; Stroik, J.; Themann, A.; Muller, C.; Woods, A.S.; Hope, B.T.; Ciruela, F.; Casado, V.; Canela, E.I.; Lluis, C.; Goldberg, S.R.; Moratalla, R.; Franco, R.; Ferre, S. Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacology, 2007, 32, 2249-2259.
72. Ellis, J.; Pediani, J.D.; Canals, M.; Milasta, S.; Milligan, G. Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. J. Biol. Chem., 2006, 281, 38812-38824.
73. Canals, M.; Milligan, G. Constitutive activity of the cannabinoid CB1 receptor regulates the function of co-expressed Mu opioid receptors. J. Biol. Chem., 2008, 283, 11424-11434.
74. Carriba, P.; Navarro, G.; Ciruela, F.; Ferre, S.; Casado, V.; Agnati, L.; Cortes, A.; Mallol, J.; Fuxe, K.; Canela, E.I.; Lluis, C.; Franco, R. Detection of heteromerization of more than two proteins by sequential BRET-FRET. Nat. Methods, 2008, 5(8), 727-733.
75. Lowes, V.L.; Ip, N.Y.; Wong, Y. H. Integration of signals from receptor tyrosine kinases and g protein-coupled receptors. Neurosignals, 2002, 11, 5-19.
76. Ferguson, S.S. Receptor tyrosine kinase transactivation: fine-tuning synaptic transmission. Trends Neurosci., 2003, 26, 119-122.
77. Shah, B.H.; Catt, K.J. GPCR-mediated transactivation of RTKs in the CNS: mechanisms and consequences. Trends Neurosci., 2004, 27, 48-53.
78. Bouaboula, M.; Perrachon, S.; Milligan, L.; Canat, X.; Rinaldi-Carmona, M.; Portier, M.; Barth, F.; Calandra, B.; Pecceu, F.; Lupker, J.; Maffrand, J.P.; Le Fur, G.; Casellas, P. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1: evidence for a new model of receptor/ligand interactions. J. Biol. Chem., 1997, 272, 22330-22339.
79. Hart, S.; Fischer, O.M.; Ullrich, A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res., 2004, 64, 1943-1950.
80. Rubovitch, V.; Gafni, M.; Sarne, Y. The cannabinoid agonist DALN positively modulates L-type voltage-dependent calcium-channels in N18TG2 neuroblastoma cells. Brain Res. Mol. Brain Res., 2002, 101, 93-102.
81. 2+ flux into N18TG2 neuroblastoma cells. Brain Res. Mol. Brain Res., 2004, 120, 138-144.
82. Cai, H.; Smola, U.; Wixler, V.; Eisenmann-Tappe, I.; Diaz-Meco, M.T.; Moscat, J.; Rapp, U.; Cooper, G.M. Role of diacylglycerol-regulated protein kinase C isotypes in growth factor activation of the Raf-1 protein kinase. Mol. Cell Biol., 1997, 17, 732-741.
83. Belcheva, M.M.; Coscia, C.J. Diversity of G protein-coupled receptor signaling pathways to ERK/MAP kinase. Neurosignals, 2002, 11, 34-44.
84. Korzh, A.; Keren, O.; Gafni, M.; Bar-Josef, H.; Sarne, Y. Modulation of extracellular signal-regulated kinase (ERK) by opioid and cannabinoid receptors that are expressed in the same cell. Brain Res., 2008, 1189, 23-32.
85. Gomez del Pulgar, T.; Velasco, G.; Guzman, M. The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem. J., 2000, 347, 369-373.
86. Galve-Roperh, I.; Rueda, D.; Gomez del Pulgar, T.; Velasco, G.; Guzman, M. Mechanism of extracellular signal-regulated kinase activation by the CB(1) cannabinoid receptor. Mol. Pharmacol., 2002, 62, 1385-1392.
87. Chan, G.C.; Hinds, T.R.; Impey, S.; Storm, D.R. Hippocampal neurotoxicity of Delta9-tetrahydrocannabinol. J. Neurosci., 1998, 18, 5322-5332.
88. Ho, R.; Ortiz, D.; Shea, T.B. Amyloid-beta promotes calcium influx and neurodegeneration via stimulation of L voltage-sensitive calcium channels rather than NMDA channels in cultured neurons. J. Alzheimers Dis., 2001, 3, 479-483.
89. Pozzoli, G.; Tringali, G.; Vairano, M.; D'Amico, M.; Navarra, P.; Martire, M. Cannabinoid agonist WIN55,212-2 induces apoptosis in cerebellar granule cells via activation of the CB1 receptor and downregulation of bcl-xL gene expression. J. Neurosci. Res., 2006, 83, 1058-1065.
90. Berghuis, P.; Dobszay, M.B.; Wang, X.; Spano, S.; Ledda, F.; Sousa, K.M.; Schulte, G.; Ernfors, P.; Mackie, K.; Paratcha, G.; Hurd, Y.L.; Harkany, T. Endocannabinoids regulate interneuron migration and morphogenesis by transactivating the TrkB receptor. Proc. Natl. Acad. Sci. USA, 2005, 102, 19115-19120.
91. Pagotto, U.; Marsicano, G.; Cota, D.; Lutz, B.; Pasquali, R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr. Rev., 2006, 27, 73-100.
92. Cota, D.; Tschop, M.H.; Horvath, T.L.; Levine, A.S. Cannabinoids, opioids and eating behavior: the molecular face of hedonism? Brain Res. Rev., 2006, 51, 85-107.
93. Kirkham, T.C. Endocannabinoids in the regulation of appetite and body weight. Behav. Pharmacol., 2005, 16, 297-313.
94. Cota, D. CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes Metab. Res. Rev., 2007, 23, 507-517.
95. Batkai, S.; Jarai, Z.; Wagner, J.A.; Goparaju, S.K.; Varga, K.; Liu, J.; Wang, L.; Mirshahi, F.; Khanolkar, A.D.; Makriyannis, A.; Urbaschek, R.; Garcia, N., Jr.; Sanyal, A.J.; Kunos, G. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat. Med., 2001, 7, 827-832.
96. Osei-Hyiaman, D.; Depetrillo, M.; Pacher, P.; Liu, J.; Radaeva, S.; Batkai, S.; Harvey-White, J.; Mackie, K.; Offertaler, L.; Wang, L.; Kunos, G. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Invest., 2005, 115, 1298-1305.
97. Osei-Hyiaman, D.; Liu, J.; Zhou, L.; Godlewski, G.; Harvey-White, J.; Jeong, W.I.; Batkai, S.; Marsicano, G.; Lutz, B.; Buettner, C.; Kunos, G. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J. Clin. Invest., 2008, 118, 3160-3169.
98. Siegmund, S.V.; Uchinami, H.; Osawa, Y.; Brenner, D.A.; Schwabe, R.F. Anandamide induces necrosis in primary hepatic stellate cells. Hepatology, 2005, 41, 1085-1095.
99. Siegmund, S.V.; Qian, T.; de Minicis, S.; Harvey-White, J.; Kunos, G.; Vinod, K.Y.; Hungund, B.; Schwabe, R.F. The endocannabinoid 2-arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species. FASEB J., 2007, 21, 2798-2806.
100. Julien, B.; Grenard, P.; Teixeira-Clerc, F.; Van Nhieu, J.T.; Li, L.; Karsak, M.; Zimmer, A.; Mallat, A.; Lotersztajn, S. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology, 2005, 128, 742-755.
101. Siegmund, S.V.; Schwabe, R.F. Endocannabinoids and liver disease. II: endocannabinoids in the pathogenesis and treatment of liver fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol., 2008, 294, G357-G362.
102. Jeong, W.I.; Osei-Hyiaman, D.; Park, O.; Liu, J.; Batkai, S.; Mukhopadhyay, P.; Horiguchi, N.; Harvey-White, J.; Marsicano, G.; Lutz, B.; Gao, B.; Kunos, G. Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab., 2008, 7 , 227-235.
103. Migliarini, B.; Carnevali, O. Anandamide modulates growth and lipid metabolism in the zebrafish Danio rerio. Mol. Cell Endocrinol., 2008, 286, S12-S16.
104. Moezi, L.; Rezayat, M.; Samini, M.; Shafaroodi, H.; Mehr, S.E.; Ebrahimkhani, M.R.; Dehpour, A.R. Potentiation of anandamide effects in mesenteric beds isolated from bile duct-ligated rats: role of nitric oxide. Eur. J. Pharmacol., 2004, 486, 53-59.
105. Siegmund, S.V.; Seki, E.; Osawa, Y.; Uchinami, H.; Cravatt, B.F.; Schwabe, R.F. Fatty acid amide hydrolase determines anandamide-induced cell death in the liver. J. Biol. Chem., 2006, 281, 10431-10438.
106. Moezi, L.; Gaskari, S.A.; Liu, H.; Baik, S.K.; Dehpour, A.R.; Lee, S.S. Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB(1) and VR(1) receptors. Br. J. Pharmacol., 2006, 149, 898-908.
107. Sandoval, D.; Cota, D.; Seeley, R.J. The integrative role of CNS fuel-sensing mechanisms in energy balance and glucose regulation. Annu. Rev. Physiol., 2008, 70, 513-535.
108. Kola, B.; Hubina, E.; Tucci, S.A.; Kirkham, T.C.; Garcia, E.A.; Mitchell, S.E.; Williams, L.M.; Hawley, S.A.; Hardie, D.G.; Grossman, A.B.; Korbonits, M. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J. Biol. Chem., 2005, 280, 25196-25201.
109. Misra, P. AMP activated protein kinase: a next generation target for total metabolic control. Expert Opin. Ther. Targets, 2008, 12, 91-100.
110. Lee, Y.M.; Uhm, K.O.; Lee, E.S.; Kwon, J.; Park, S.H.; Kim, H.S. AM251 suppresses the viability of HepG2 cells through the AMPK (AMP-activated protein kinase)-JNK (c-Jun N-terminal kinase)-ATF3 (activating transcription factor 3) pathway. Biochem. Biophys. Res. Commun., 2008, 370, 641-645.
111. Tedesco, L.; Valerio, A.; Cervino, C.; Cardile, A.; Pagano, C.; Vettor, R.; Pasquali, R.; Carruba, M.O.; Marsicano, G.; Lutz, B.; Pagotto, U.; Nisoli, E. Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes. Diabetes, 2008, 57, 2028-2036.
112. Gross, B.; Staels, B. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. Best. Pract. Res. Clin. Endocrinol. Metab., 2007, 21, 687-710.
113. Lee, C.H.; Olson, P.; Evans, R.M. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology, 2003, 144, 2201-2207.
114. O'Sullivan, S.E. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br. J. Pharmacol., 2007, 152, 576-582.
115. LoVerme, J.; La Rana, G.; Russo, R.; Calignano, A.; Piomelli, D. The search for the palmitoylethanolamide receptor. Life Sci., 2005, 77, 1685-1698.
116. Sun, Y.; Alexander, S.P.; Garle, M.J.; Gibson, C.L.; Hewitt, K.; Murphy, S.P.; Kendall, D.A.; Bennett, A.J. Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. Br. J. Pharmacol., 2007, 152, 734-743.
117. Jhaveri, M.D.; Richardson, D.; Robinson, I.; Garle, M.J.; Patel, A.; Sun, Y.; Sagar, D.R.; Bennett, A.J.; Alexander, S.P.; Kendall, D.A.; Barrett, D.A.; Chapman, V. Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain. Neuropharmacology, 2008, 55, 85-93.
118. Boring, D.L.; Berglund, B.A.; Howlett, A.C. Cerebrodiene, arachidonyl-ethanolamide, and hybrid structures: potential for interaction with brain cannabinoid receptors. Prostaglandins Leukot. Essent. Fatty Acids, 1996, 55, 207-210.
119. Rodriguez, D.F.; Navarro, M.; Gomez, R.; Escuredo, L.; Nava, F.; Fu, J.; Murillo-Rodriguez, E.; Giuffrida, A.; LoVerme, J.; Gaetani, S.; Kathuria, S.; Gall, C.; Piomelli, D. An anorexic lipid mediator regulated by feeding. Nature, 2001, 414, 209-212.
120. Gaetani, S.; Oveisi, F.; Piomelli, D. Modulation of meal pattern in the rat by the anorexic lipid mediator oleoylethanolamide. Neuropsychopharmacology, 2003, 28, 1311-1316.
121. Proulx, K.; Cota, D.; Castaneda, T.R.; Tschop, M.H.; D'Alessio, D.A.; Tso, P.; Woods, S.C.; Seeley, R.J. Mechanisms of oleoylethanolamide-induced changes in feeding behavior and motor activity. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2005, 289, R729-R737.
122. Fu, J.; Gaetani, S.; Oveisi, F.; Lo, V.J.; Serrano, A.; Rodriguez, D.F.; Rosengarth, A.; Luecke, H.; Di Giacomo, B.; Tarzia, G.; Piomelli, D. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature, 2003, 425, 90-93.
123. Guzman, M.; Lo, V.J.; Fu, J.; Oveisi, F.; Blazquez, C.; Piomelli, D. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha). J. Biol. Chem., 2004, 279, 27849-27854.
124. Cota, D.; Marsicano, G.; Tschop, M.; Grubler, Y.; Flachskamm, C.; Schubert, M.; Auer, D.; Yassouridis, A.; Thone-Reineke, C.; Ortmann, S.; Tomassoni, F.; Cervino, C.; Nisoli, E.; Linthorst, A.C.; Pasquali, R.; Lutz, B.; Stalla, G.K.; Pagotto, U. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest., 2003, 112, 423-431.
125. Bensaid, M.; Gary-Bobo, M.; Esclangon, A.; Maffrand, J.P.; Le Fur, G.; Oury-Donat, F.; Soubrie, P. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol. Pharmacol., 2003, 63, 908-914.
126. Gary-Bobo, M.; Elachouri, G.; Scatton, B.; Le Fur, G.; Oury-Donat, F.; Bensaid, M. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol. Pharmacol., 2006, 69, 471-478.
127. Yan, Z.C.; Liu, D.Y.; Zhang, L.L.; Shen, C.Y.; Ma, Q.L.; Cao, T.B.; Wang, L.J.; Nie, H.; Zidek, W.; Tepel, M.; Zhu, Z.M. Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferator-activated receptor-delta. Biochem. Biophys. Res. Commun., 2007, 354, 427-433.
128. Matias, I.; Gonthier, M.P.; Orlando, P.; Martiadis, V.; De Petrocellis, L.; Cervino, C.; Petrosino, S.; Hoareau, L.; Festy, F.; Pasquali, R.; Roche, R.; Maj, M.; Pagotto, U.; Monteleone, P.; Di, M.V. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J. Clin. Endocrinol. Metab., 2006, 91, 3171-3180.
129. Roche, R.; Hoareau, L.; Bes-Houtmann, S.; Gonthier, M.P.; Laborde, C.; Baron, J.F.; Haffaf, Y.; Cesari, M.; Festy, F. Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes. Histochem. Cell Biol., 2006, 126, 177-187.
130. Gasperi, V.; Fezza, F.; Pasquariello, N.; Bari, M.; Oddi, S.; Agro, A.F.; Maccarrone, M. Endocannabinoids in adipocytes during differentiation and their role in glucose uptake. Cell Mol. Life Sci., 2007, 64, 219-229.
131. Valerio, A.; Cardile, A.; Cozzi, V.; Bracale, R.; Tedesco, L.; Pisconti, A.; Palomba, L.; Cantoni, O.; Clementi, E.; Moncada, S.; Carruba, M. O.; Nisoli, E. TNF-alpha downregulates eNOS expression and mitochondrial biogenesis in fat and muscle of obese rodents. J. Clin. Invest., 2006, 116, 2791-2798.
132. Mueller, E.; Drori, S.; Aiyer, A.; Yie, J.; Sarraf, P.; Chen, H.; Hauser, S.; Rosen, E.D.; Ge, K.; Roeder, R.G.; Spiegelman, B.M. Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor gamma isoforms. J. Biol. Chem., 2002, 277, 41925-41930.
133. Bouaboula, M.; Hilairet, S.; Marchand, J.; Fajas, L.; Le Fur, G.; Casellas, P. Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur. J. Pharmacol., 2005, 517, 174-181.
134. Liu, J.; Li, H.; Burstein, S.H.; Zurier, R.B.; Chen, J.D. Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid. Mol. Pharmacol., 2003, 63, 983-992.
135. O'Sullivan, S.E.; Kendall, D.A.; Randall, M.D. Heterogeneity in the mechanisms of vasorelaxation to anandamide in resistance and conduit rat mesenteric arteries. Br. J. Pharmacol., 2004, 142, 435-442.
136. O'Sullivan, S.E.; Tarling, E.J.; Bennett, A.J.; Kendall, D.A.; Randall, M.D. Novel time-dependent vascular actions of Delta9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma. Biochem. Biophys. Res. Commun., 2005, 337, 824-831.